Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05967806 · ClinicalTrials.gov registry record
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
A clinical trial of Renal Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,575
- Enrollment target
- 20
- Study locations
NCT05967806: Completed study of Renal Disease, sponsored by AstraZeneca.
NCT05967806 is a study of Renal Disease that has completed, run by AstraZeneca. The registered enrollment target is 2,575 participants, below the 195,636-participant average among 4 other Renal Disease trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05967806, a study of Renal Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,575 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions.
Primary Outcome
Summary statistics
Conditions Studied
Interventions
- PROCEDURE assessment
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Chatsworth
- Research Site - San Carlos
- Research Site - South Gate
- Research Site - Tarzana
- Research Site - Victorville
North Carolina
- Research Site - Kinston
- Research Site - New Bern
- Research Site - Wilmington
- Research Site - Winston-Salem
Other
- Research Site - Buenos Aires
- Research Site - Santa Fe
- Research Site - Belém
Florida
- Research Site - Jacksonville
- Research Site - Miami
Texas
- Research Site - Pearland
- Research Site - San Antonio
Alabama
- Research Site - Huntsville
South Carolina
- Research Site - Greenville
Virginia
- Research Site - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,575 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2024-08-30 |
What the finished NCT05967806 record still lists
NCT05967806 is an observational study that tracks outcomes without assigning an intervention. Its 2,575 participants enrollment target places it among the larger protocols in the corpus, below the 195,636-participant average among 4 other Renal Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which assessment is the first listed.
NCT05967806 names 20 study sites across 8 states, led by California, North Carolina, Other.
Frequently Asked Questions
What is clinical trial NCT05967806 about?
NCT05967806 is a clinical study titled "A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria". The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions.
What is the current status of trial NCT05967806?
This trial is currently completed. The enrollment target is 2,575 participants. The study started on 2023-07-31. Estimated completion is 2024-08-30.
What conditions does trial NCT05967806 study?
This clinical trial studies the following conditions: Renal Disease.
What interventions are being tested in trial NCT05967806?
The interventions under investigation include: assessment (PROCEDURE).
Who is sponsoring clinical trial NCT05967806?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05967806 being conducted?
This trial has 20 study locations across Alabama, California, Florida, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cooperative Assessment of Late Effects for SCD Curative Therapies
RECRUITING
-
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
ACTIVE NOT RECRUITING
-
Outlook: An Intervention to Improve Quality of Life in Serious Illness
COMPLETED · NA
-
A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI